1. Home
  2. TVTX vs UMH Comparison

TVTX vs UMH Comparison

Compare TVTX & UMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • UMH
  • Stock Information
  • Founded
  • TVTX 2008
  • UMH 1968
  • Country
  • TVTX United States
  • UMH United States
  • Employees
  • TVTX N/A
  • UMH N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • UMH Real Estate Investment Trusts
  • Sector
  • TVTX Health Care
  • UMH Real Estate
  • Exchange
  • TVTX Nasdaq
  • UMH Nasdaq
  • Market Cap
  • TVTX 1.7B
  • UMH 1.4B
  • IPO Year
  • TVTX N/A
  • UMH N/A
  • Fundamental
  • Price
  • TVTX $15.02
  • UMH $16.80
  • Analyst Decision
  • TVTX Strong Buy
  • UMH Strong Buy
  • Analyst Count
  • TVTX 14
  • UMH 4
  • Target Price
  • TVTX $33.31
  • UMH $21.00
  • AVG Volume (30 Days)
  • TVTX 1.9M
  • UMH 414.2K
  • Earning Date
  • TVTX 05-01-2025
  • UMH 05-01-2025
  • Dividend Yield
  • TVTX N/A
  • UMH 5.36%
  • EPS Growth
  • TVTX N/A
  • UMH N/A
  • EPS
  • TVTX N/A
  • UMH 0.10
  • Revenue
  • TVTX $273,533,000.00
  • UMH $243,777,000.00
  • Revenue This Year
  • TVTX $74.41
  • UMH $10.29
  • Revenue Next Year
  • TVTX $48.90
  • UMH $7.55
  • P/E Ratio
  • TVTX N/A
  • UMH $161.66
  • Revenue Growth
  • TVTX 75.65
  • UMH 8.17
  • 52 Week Low
  • TVTX $6.79
  • UMH $14.87
  • 52 Week High
  • TVTX $25.29
  • UMH $20.64
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 35.45
  • UMH 43.28
  • Support Level
  • TVTX $16.37
  • UMH $16.18
  • Resistance Level
  • TVTX $15.48
  • UMH $16.88
  • Average True Range (ATR)
  • TVTX 1.00
  • UMH 0.32
  • MACD
  • TVTX -0.51
  • UMH -0.00
  • Stochastic Oscillator
  • TVTX 3.83
  • UMH 48.06

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About UMH UMH Properties Inc.

UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.

Share on Social Networks: